Peetz Christopher, CEO, reported an open-market or private sale at Mirum Pharmaceuticals, Inc. involving 21688.000000 shares for an estimated $2145160.08. Reported holdings after the transaction were 194440.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
CHIEF EXECUTIVE OFFICER
Includes 131 shares of Common Stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.
Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
The weighted average sale price for the transaction reported was $98.08, and the range of prices were between $97.47 and $98.42. Upon request by the SEC staff, the Issuer, or any security holder of th…
The weighted average sale price for the transaction reported was $98.91, and the range of prices were between $98.49 and $99.38. Upon request by the SEC staff, the Issuer, or any security holder of th…
The stock option is fully vested.
0 other filings
0 recent txs